Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

22-08-2018 | Original Paper

Prevalence of Psychotropic Medicine Use in Australian Children with Autism Spectrum Disorder: A Drug Utilization Study Based on Children Enrolled in the Longitudinal Study of Australian Children

Auteurs: Lotte Rasmussen, Nicole Pratt, Elizabeth Roughead, Anna Moffat

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 1/2019

Abstract

Based on data from the Longitudinal Study of Australian Children linked with pharmacy dispensing data from the Australian Government’s Pharmaceutical Benefits Scheme, we calculated the 1-year prevalence of psychotropic medicine supply in children and adolescents with Autism Spectrum Disorder (ASD) as reported by parents in 2014. The majority of children and adolescents with ASD in Australia were not treated with psychotropic medicine. One-third had claims for at least one psychotropic medication, most commonly medications for attention-deficit/hyperactivity disorder (ADHD), and antidepressants. Antipsychotics were supplied to less than one in twenty children and approximately one in ten adolescents. In line with findings from North America, psychotropic medicine was more often supplied to children and adolescents with ASD and comorbid ADHD.

vorige artikel Maternal Interactive Behaviours in Parenting Children with Williams Syndrome and Autism Spectrum Disorder: Relations with Emotional/Behavioural Problems

volgende artikel Effects of Joint Video Modeling on Unscripted Play Behavior of Children with Autism Spectrum Disorder

Australian Bureau of Statistics. (n.d.). Autism in Australia, 2012. Retrieved from http://www.abs.gov.au/AUSSTATS/abs@.nsf/Latestproducts/4428.0Main%20Features32012.

Australian Government Department of Health. (n.d.). Pharmaceutical Benefits Scheme (PBS). Retrieved from http://www.pbs.gov.au/pbs/home.

Barbaro, J., Ridgway, L., & Dissanayake, C. (2011). Developmental surveillance of infants and toddlers by maternal and child health nurses in an australian community-based setting: Promoting the early identification of autism spectrum disorders. Journal of Pediatric Nursing, 26(4), 334–347. https://doi.org/10.1016/j.pedn.2010.04.007.CrossRefPubMed

Blakemore, T., Strazdins, L., & Gibbings, J. (2009). Measuring family socio-economic position. Australian Social Policy, 8, 121–168.

Coury, D. L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., McCoy, R., et al. (2012). Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics, 130(Supplement 2), S69–S76. https://doi.org/10.1542/peds.2012-0900D.CrossRefPubMed

Doyle, C. A., & McDougle, C. J. (2012). Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opinion on Pharmacotherapy, 13(11), 1615–1629. https://doi.org/10.1517/14656566.2012.674110.CrossRefPubMed

Earle, J. F. (2016). An introduction to the psychopharmacology of children and adolescents with autism spectrum disorder: An introduction to the psychopharmacology of children and adolescents with autism spectrum disorder. Journal of Child and Adolescent Psychiatric Nursing, 29(2), 62–71. https://doi.org/10.1111/jcap.12144.CrossRefPubMed

Elsabbagh, M., Divan, G., Koh, Y.-J., Kim, Y. S., Kauchali, S., Marcín, C., et al. (2012). Global prevalence of autism and other pervasive developmental disorders: Global epidemiology of autism. Autism Research, 5(3), 160–179. https://doi.org/10.1002/aur.239.CrossRefPubMedPubMedCentral

Fombonne, E. (2003). Epidemiological surveys of autism and other pervasive developmental disorders: An update. Journal of Autism and Developmental Disorders, 33(4), 365–382.CrossRef

Frazier, T. W., Shattuck, P. T., Narendorf, S. C., Cooper, B. P., Wagner, M., & Spitznagel, E. L. (2011). Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 21(6), 571–579. https://doi.org/10.1089/cap.2011.0057.CrossRefPubMedPubMedCentral

Goldin, R. L., Matson, J. L., Tureck, K., Cervantes, P. E., & Jang, J. (2013). A comparison of tantrum behavior profiles in children with ASD, ADHD and comorbid ASD and ADHD. Research in Developmental Disabilities, 34(9), 2669–2675. https://doi.org/10.1016/j.ridd.2013.04.022.CrossRefPubMed

Growing Up in Australia. (n.d.). Retrieved from http://www.growingupinaustralia.gov.au/.

Growing Up in Australia. (n.d.). The longitudinal study of Australian children data user guide. Retrieved from http://www.growingupinaustralia.gov.au/data/docs/userguide/5-filestructure.html.

Growing Up in Australia. The longitudinal study of Australian children (LSAC) LSAC technical paper no. 17 using Australian childhood immunisation register data in the longitudinal study of Australian children. (n.d.). Retrieved from http://growingupinaustralia.gov.au/pubs/technical/tp17.pdf.

Houghton, R., Ong, R. C., & Bolognani, F. (2017). Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States: Psychotropic medications in autism in the US. Autism Research. https://doi.org/10.1002/aur.1848.CrossRefPubMed

Jang, J., Matson, J. L., Williams, L. W., Tureck, K., Goldin, R. L., & Cervantes, P. E. (2013). Rates of comorbid symptoms in children with ASD, ADHD, and comorbid ASD and ADHD. Research in Developmental Disabilities, 34(8), 2369–2378. https://doi.org/10.1016/j.ridd.2013.04.021.CrossRefPubMed

Jobski, K., Höfer, J., Hoffmann, F., & Bachmann, C. (2017). Use of psychotropic drugs in patients with autism spectrum disorders: A systematic review. Acta Psychiatrica Scandinavica, 135(1), 8–28. https://doi.org/10.1111/acps.12644.CrossRefPubMed

Lai, M.-C., Lombardo, M. V., & Baron-Cohen, S. (2014). Autism. The Lancet, 383(9920), 896–910. https://doi.org/10.1016/S0140-6736(13)61539-1.CrossRef

May, T., Sciberras, E., Brignell, A., & Williams, K. (2017). Autism spectrum disorder: Updated prevalence and comparison of two birth cohorts in a nationally representative Australian sample. British Medical Journal Open, 7(5), e015549. https://doi.org/10.1136/bmjopen-2016-015549.CrossRef

Randall, M., Sciberras, E., Brignell, A., Ihsen, E., Efron, D., Dissanayake, C., & Williams, K. (2016). Autism spectrum disorder: Presentation and prevalence in a nationally representative Australian sample. Australian & New Zealand Journal of Psychiatry, 50(3), 243–253.CrossRef

Sprenger, L., Bühler, E., Poustka, L., Bach, C., Heinzel-Gutenbrunner, M., Kamp-Becker, I., & Bachmann, C. (2013). Impact of ADHD symptoms on autism spectrum disorder symptom severity. Research in Developmental Disabilities, 34(10), 3545–3552. https://doi.org/10.1016/j.ridd.2013.07.028.CrossRefPubMed

Sturman, N., Deckx, L., & van Driel, M. L. (2017). Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD011144.pub2.CrossRefPubMed

The Pharmaceutical Benefits Scheme. (n.d.). Risperidone. Retrieved from http://www.pbs.gov.au/medicine/item/1842Y-1846E.

Williams, K., Brignell, A., Randall, M., Silove, N., & Hazell, P. (2013). Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). In The Cochrane Collaboration (Ed.), Cochrane database of systematic reviews. Chichester: Wiley. https://doi.org/10.1002/14651858.CD004677.pub3.CrossRef

Williams, K., MacDermott, S., Ridley, G., Glasson, E. J., & Wray, J. A. (2008). The prevalence of autism in Australia. Can it be established from existing data? Journal of Paediatrics and Child Health, 44(9), 504–510. https://doi.org/10.1111/j.1440-1754.2008.01331.x.CrossRefPubMed

Wong, A. Y. S., Hsia, Y., Chan, E. W., Murphy, D. G. M., Simonoff, E., Buitelaar, J. K., & Wong, I. C. K. (2014). The variation of psychopharmacological prescription rates for people with autism spectrum disorder (ASD) in 30 countries. Autism Research: Official Journal of the International Society for Autism Research, 7(5), 543–554. https://doi.org/10.1002/aur.1391.CrossRef

Young, N., & Findling, R. L. (2015). An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Current Opinion in Psychiatry. https://doi.org/10.1097/YCO.0000000000000132.CrossRef

Titel: Prevalence of Psychotropic Medicine Use in Australian Children with Autism Spectrum Disorder: A Drug Utilization Study Based on Children Enrolled in the Longitudinal Study of Australian Children
Auteurs: Lotte Rasmussen
Nicole Pratt
Elizabeth Roughead
Anna Moffat
Publicatiedatum: 22-08-2018
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 1/2019
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-018-3718-3

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 1/2019

Correction to: Physical health in children with neurodevelopmental disorders

Higher Tactile Temporal Resolution as a Basis of Hypersensitivity in Individuals with Autism Spectrum Disorder

Brief Report: Flanker Visual Filtering Ability in Older Adolescents with Autism Spectrum Disorder

Roles, Strengths and Challenges of Using Robots in Interventions for Children with Autism Spectrum Disorder (ASD)

Parental Perceptions of the Nature of the Relationship Children with Autism Spectrum Disorders Share with Their Canine Companion

Interrupted Time Experience in Autism Spectrum Disorder: Empirical Evidence from Content Analysis